Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Not yet recruiting2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 32 (100.0%)

Trials by Status

not_yet_recruiting267%
enrolling_by_invitation133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

NCT06525389
not_yet_recruitingphase_3

Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)

NCT07463040
enrolling_by_invitation

L-AmB_ Retrospective mUlticenter Study on Mycosis prOphylaxis

NCT06640296

Clinical Trials (3)

Showing 3 of 3 trials
NCT06525389Phase 3

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Not Yet Recruiting
NCT07463040Phase 3

Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)

Not Yet Recruiting
NCT06640296

L-AmB_ Retrospective mUlticenter Study on Mycosis prOphylaxis

Enrolling By Invitation

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3